17p Anomalies in Lymphoid Malignancies: Diagnostic and Prognostic Implications

References

• Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Lane D. P., Benchimol S. p53: oncogene or antionco-gene?. Genes & Development 1990; 4: 1–8
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Fearon F. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M. M., Bos J. L. Genetic Alterations during colorectal-tumor development. N. Eng. J. Med. 1988; 319: 525–532
   PubMed Web of Science ®Google Scholar
• Baker S. J., Preisinger A. C., Jessup J. M., Paraskeva C., Markowitz S., Willson J. K. V., Hamilton S., Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50: 7717–7722
   PubMed Web of Science ®Google Scholar
• Borgstrom G. H., Vuopio P., de la Chapelle A. Abnormalities of chromosome No. 17 in myeloproliferative disorders. Cancer Genetics and Cytogenetics 1982; 5: 123–135
   PubMed Web of Science ®Google Scholar
• Jonveaux P., Berger R. Chromosomal deletions in Non-Hodgkin's malignant lymphoma. Cancer Genetics Cytogenetics 1990; 49: 265–269
   PubMed Web of Science ®Google Scholar
• Levine E. G., Arthur D. C., Frizzera G., Peterson B. A., Hurd D. D., Bloomfield C. D. Cytogenetic abnormalities predict clinical outcome in Non-Hodgkin Lymphoma. Ann. Int. Med. 1988; 108: 14–20
   PubMed Web of Science ®Google Scholar
• Levine E. G., Juneija S., Arthur D., Garson O. M., Machniki J. L., Frizzera G., Ironside P., Cooper I., Hurd D. D., Peterson B. A., Mosel D., Bloomfield C. Sequential Karyotypes in Non-Hodgkin Lymphoma: Their nature and significance. Genes, Chromosomes & Cancer 1990; 1: 270–280
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Pathak S., Grant G., Hegemeister F. B., McLaughlin P., Swan F., Rodriguez M. A., Trujillo J., Cork A., Butler J. J., Katz R., Bourne S., Freireich E. J. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am. J. Med. 1989; 87: 167–172
   PubMed Web of Science ®Google Scholar
• Schouten H. C., Sanger W. G., Weisenburger D. D., Anderson J., Armitage J. O. Chromosomal abnormalities in untreated patients with Non-Hodgkin's lymphoma: Association with histology, clinical characteristics, and treatment outcome. Blood 1990; 75(9)1841–1847
   PubMed Web of Science ®Google Scholar
• Kristofferson U., Heim S., Mandahl N., Olsson H., Ranstam J., Akerman M., Mitelman F. Prognostic implication of cytogenetic findings in 106 patients with Non-Hodgkin lymphoma. Cancer Genetics Cytogenetics 1987; 25: 55–64
   PubMed Web of Science ®Google Scholar
• Heim S., Mitelman F. Secondary chromosome aberrations in the acute leukemias. Cancer Genetics Cytogenetics 1986; 22: 331–338
   PubMed Web of Science ®Google Scholar
• Heim S., Mitelman F. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 1992; 70: 1701–1709
   PubMed Web of Science ®Google Scholar
• Pui C. H., Carroll A. J., Raimondi S. C., Schell M. J., Head D. R., Shuster J. J., Crist W. M., Borowitz M. J., Link M. P., Behm F. G., Steuber C. P., Land V. I. Isochromosomes in childhood acute lymphoblastic leukemia: A collaborative study of 83 cases. Blood 1992; 79(9)2384–2391
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Raimondi S. C., Williams D. L. Isochromosome 17q in childhood acute lymphoblastic leukemia: An adverse cytogenetic feature in association with hyperdiploidy?. Leukemia 1988; 2(4)222–225
   PubMed Web of Science ®Google Scholar
• Stollmann B., Fonatsch Ch., Havers W. Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders. Br. J. Haematol. 1985; 60: 183–196
   PubMed Web of Science ®Google Scholar
• Fonatsch Ch., Schaadt M., Kirchner H., Diehl V. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Internatl. J. Cancer 1980; 26: 749–756
   PubMed Web of Science ®Google Scholar
• ISCN. Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature (1991). S. Karger, Publisher. 1991
   Google Scholar
• Rieder H., Kolbus U., Koop U., Ludwig W.-D., Stollmann-Gibbels B., Fonatsch Ch. Translocation t(1;22) mimicking t(I; 19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting. Leukemia 1993; 7(10)1663–1666
   PubMed Web of Science ®Google Scholar
• Soini Y., Paeaekkoe P., Alavaikko M., Vaehaekangas K. p53 expression in lymphatic malignancies. J. Clin. Pathol. 1992; 45(11)1011–1014
   PubMed Web of Science ®Google Scholar
• Ichikawa A., Hotta T., Takagi N., Kinoshita T., Nagai H., Murakami Y., Hayashi K., Saito H. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992; 79b(10)2701–2707
   Google Scholar
• Lo Coco F., Gaidano G., Louie D. C., Offit K., Chaganti R. S. K., Dalla-Favera. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82(8)2289–2295
   PubMed Web of Science ®Google Scholar
• Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Nerti A., Newcomb E. W., Magrath I. T., Knowles D. M., Dala-Favera R. p53 mutations in lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Lehtinen T., Isola J., Aine R., Alavaikko M., Lehtinen M. Accumulation of p53 protein correlates with tumour proliferative activity in EBV positive Burkitt's lymphoma. Hematol. Oncol. 1992; 10(5): 273–279
   Web of Science ®Google Scholar
• Villuendas R., Pins M. A., Orradre J. L., Mollejo M., Algara P., Sanchez L., Martinez J. C., Martinez P. p53 protein expression in lymphomas and reactive lymphoid tissue. J. Pathol. 1992; 166: 235–241
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Preudhomme C., Lai J. L., Vanrumbeke M., Loucheux-Lefebvre M. H., Bauters F., Berger R., Kerckaert J. P. Mutations of the p53 gene in B-cell lymphoblastic leukemia: A report of 60 cases. Leukemia 1992; 6(1)42–46
   PubMed Web of Science ®Google Scholar
• Farrel P. J., Allan G. J., Shanahan F., Vousden K. H., Crook T. p53 is frequently mutated in Burkitt' s lymphoma cell lines. EMBO J. 1991; 10(10)2879–2887
   PubMed Web of Science ®Google Scholar
• Wiman K. C., Magnusson K. P., Ramqvist T., Klein G. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 1991; 6: 1633–1639
   PubMed Web of Science ®Google Scholar
• Taylor W. R., Egan S. E., Mowat M., Greenberg A. H., Wright J. A. Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 1992; 7(7)1383–1390
   PubMed Web of Science ®Google Scholar
• Scheuermann R. H., Bauer S. R. Loss of p53 expression in myc-induced B lineage tumors. Current Topics in Microbiology and Immunology 1992; 182: 493–499
   PubMedGoogle Scholar
• Rodriguez M. A., Ford R. J., Goodacre A., Selvanayagam P., Cabanillas F., Deisseroth A. B. Chromosome 17p and p53 changes in lymphoma. Br. J. Haematol. 1991; 79: 575–582
   PubMed Web of Science ®Google Scholar
• Florelos T., Heisterkamp N., Groffen J., Benjes S., Morris C. CRK protooncogene maps to human chromosome band 17p13. Oncogene 1993; 8(10)2853–2855
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S. L., Goldman J., Snyder D., Foti A., Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991; 87: 2042–2047
   PubMed Web of Science ®Google Scholar
• Mashal R., Shtalrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J., Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Tanaka S., Nishigaki H., Taniwaki M., Yokota S., Horiike S., Takashima T., Seriu T., Nakagawa H., Fujii H., Shimazaki C., Okada H., Toguchida J., Abe T., Kashima K. p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia. Leukemia. 1993; 7(10)1547–1551
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P., Larsen S. O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990; 76(6)1083–1091
   PubMed Web of Science ®Google Scholar
• Fagioli F., Cuneo A., Piva N., Carli M. G., Previati R., Balboni M., Tomasi P., Cariani D., Scapoli G., Castoldi G. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer 1992; 70(1)77–85
   PubMed Web of Science ®Google Scholar
• Lane D. P. p53, guardian of the genome. Nature 1992; 358: 15–16
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345–347
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Earl, Ruley H., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967
   PubMed Web of Science ®Google Scholar